PSA Net vs Cancer Risk
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
PSA Net
This medical app uses a neural network to predict the likelihood of prostate cancer on biopsy. It considers patient data such as age, PSA levels, symptom scores, ethnicity, family history, and rectal exam results. It is designed for use by qualified healthcare professionals.
- Prostate cancer prediction
- Neural network analysis
- Patient data input
- Biopsy likelihood assessment
- Healthcare professional tool
Read full descriptionHide full description
PSA Net is a neural network that predicts whether a man will have prostate cancer on biopsy from the patient's age, total PSA, complexed PSA, results of the International Prostate Symptom Score, ethnicity, family history and rectal exam. It is intended to be used by qualified healthcare professionals. The application is an adaptation of the algorithm published in Kalra P, Togami J, Bansal B S G, Partin AW, Brawer MK, Babaian RJ, Ross LS, Niederberger CS: A neurocomputational model for prostate carcinoma detection: Cancer 2003 Nov 1;98(9):1849-54.
Cancer Risk
This medical tool calculates your general risk of prostate cancer based on your PSA level and other factors. It is designed to assist in risk assessment, not provide a definitive diagnosis. Always consult a healthcare professional for health decisions.
- Prostate cancer risk calculation
- Based on ERSPC Rotterdam data
- Supports PSA level input
- Assists in risk assessment
- Developed for iOS
Read full descriptionHide full description
The Rotterdam Prostate Cancer Risk Calculator is based on ERSPC, Rotterdam, data and supported by the Prostate Cancer Research Foundation, Rotterdam (SWOP) The Prostate Cancer Research Foundation, Rotterdam, Stichting Wetenschappelijk Onderzoek Prostaatkanker (SWOP), is an initiative of the Department of Urology of the Erasmus MC, the University and Medical Centre of Rotterdam, in The Netherlands. Its goal is the financial support of scientific research projects in the field of prostate cancer, as well as other cancers of the urinary tract. Please be aware that the Rotterdam Prostate Cancer Risk Calculator for iOS cannot be 100% accurate at predicting the presence or absence of prostate cancer. It is designed to help calculate your risk, not give a definitive diagnosis. The Rotterdam Prostate Cancer Risk Calculator for iOS provides a general risk calculation based on your PSA level and other information. While knowing your PSA level is helpful, the decision to have a PSA test has to be taken seriously after weighing up all factors and discussing the implications with your GP or hospital doctor. It is possible that prostate cancer will not be found even if you have an elevated PSA. However, it may be present even if your PSA level is low. Your doctor may want to take further tests. If you have doubts or questions about your health, you should always contact your GP or hospital doctor. This is particularly important if you have questions which arise from the use of our prostate cancer risk calculator. It cannot be ruled out that the way the Rotterdam Prostate Cancer Risk Calculator for iOS is used, or the indications given by it, are interpreted in a manner that is not appropriate. The creators of the Rotterdam Prostate Cancer Risk Calculator for iOS do not accept any responsibility in any respect. The European Randomized Study of Screening for Prostate Cancer has published its 11-year follow-up results (New England Journal of Medicine, March 15 2012). Once again, they demonstrate that screening does significantly reduce death from prostate cancer. The latest study confirms that a man who undergoes PSA testing will have his risk of dying from prostate cancer reduced by 29%. ERSPC is the world’s largest randomized prostate cancer screening study. It was designed to investigate whether early detection and treatment of prostate cancer might reduce disease-specific mortality and also help to identify men at risk. From 1992, the ERSPC study randomized 162,000 men, aged 55 to 69, across Europe to either a screening arm or a control group. Designed and developed for iOS by Nuno Azevedo of Ydeal.net Software LDA
Screenshots
Verdict
The clearest difference is price: PSA Net at Free against Cancer Risk's $1.99. PSA Net also leads on rating (2.3 vs 2.0) and ratings volume (38 vs 1). Cancer Risk's advantage is update cadence (every 3 months vs every 103 months) and device support (3 vs 1). On review sentiment, ads and in-app purchases there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
PSA Net is free to download; Cancer Risk costs $1.99 up front. Neither carries in-app purchases, so what you see is what you pay.
PSA Net holds the better App Store score, 2.3 against 2.0. That said, the two scores are not equally well evidenced: PSA Net has 38 ratings behind it against 1, so its average is the more settled of the two. Written reviews split almost evenly too, at 33% and 33% positive.
PSA Net ships an update every 103 months, Cancer Risk every 3 months. Both last shipped on October 29, 2026.
| Parameter | PSA Net | Cancer Risk |
|---|---|---|
| Price | Free — better | $1.99 |
| Rating | 2.3 (38 ratings) — better | 2.0 (1 ratings) |
| Positive reviews | 33.3% of reviews | 33.3% of reviews |
| Number of ratings | 38 — better | 1 |
| Update frequency | Every 103 months | Every 3 months — better |
| Ads | No | No |
| In-app purchases | No | No |
| Monetization | Free — better | Paid |
| Devices | iPhone | iPhone, iPad, iPod — better |
| Requires iOS | 16.6 | 14.0 — better |
| Further details — not scored | ||
| Size | 1 MB | 6 MB |
| Age rating | 4+ | 17+ |
| Developer | Niedertronics | Stichting SWOP |
Customer experience
PSA Net
Cancer Risk
In-app purchases
PSA Net
No in-app purchases
Cancer Risk
No in-app purchases








